Chieti, Italy, London , UK - Deep-vein thrombosis (DVT) and
pulmonary embolism, the potentially life-threatening disorders
in which blood clots form primarily in the legs, were prevented
in long-haul airline travelers with a history of heart disease
through a single dose of the widely prescribed antithrombotic
agent enoxaparin sodium (Clexane(R)/Lovenox(R)), according to a
new study. The San Valentino Screening Project (the Italian
equivalent of the well-known Framingham Heart Study) organised
the study known as LONFLIT III. The entire LONFLIT research
program includes more than 1500 subjects, each of whom
experienced a flight of at least 10 hours in length. LONFLIT
III, an independently funded study, enrolled 300 people with a
history of heart disease or stroke who were subsequently
subjected to a plane flight of more than 10 hours in duration.
Study participants were randomly assigned to receive either 400
mg of aspirin in one daily dose for three days (starting 12
hours before their flight), a single weigh